Can glucose‐lowering medications improve outcomes in non‐diabetic heart failure patients? A Bayesian network meta‐analysis

• Published in: ESC Heart Failure Vol. 9; no. 2; pp. 1338 - 1350
• Main Authors: Yeong, Trevor, Mai, Aaron Shengting, Lim, Oliver Z.H., Ng, Cheng Han, Chin, Yip Han, Tay, Phoebe, Lin, Chaoxing, Muthiah, Mark, Khoo, Chin Meng, Dalakoti, Mayank, Loh, Poay‐Huan, Chan, Mark, Yeo, Tiong‐Cheng, Foo, Roger, Wong, Raymond, Chew, Nicholas W.S., Lin, Weiqin
• Format: Journal Article
• Language: English
• Published: England John Wiley & Sons, Inc 01.04.2022; John Wiley and Sons Inc; Wiley
• Subjects: Antidiabetics; Bias; Clinical trials; Diabetes; Ejection fraction; Generalized linear models; GLP-1 receptor agonists; Glucagon; Glucagon‐like peptide 1 receptor agonists; Glucose; Heart Failure; Humans; Meta-analysis; Metformin; Mortality; Original; Peptides; Sodium-Glucose Transporter 2 Inhibitors - therapeutic use; Sodium‐glucose cotransporter 2 inhibitors; Glucagon-like peptide 1 receptor agonists; Heart failure; Metformin; Sodium-glucose cotransporter 2 inhibitors

Aims The cardioprotective effects of glucose‐lowering medications in diabetic patients with heart failure (HF) are well known. Several large randomized controlled trials (RCTs) have recently suggested that the cardioprotective effects of glucose‐lowering medications extend to HF patients regardless...